Skip to main content
TCRT
NASDAQ Life Sciences

Alaunos Proxy Seeks Approval to Convert Preferred Into 381.4M Shares and Lift Authorized Stock to 400M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$1.56
Mkt Cap
$6.729M
52W Low
$0.719
52W High
$4.5
52W Position info
117% above low
Off High info
65% below high
Rel. Volume
Market data snapshot near publication time

TCRT has more than doubled off its 52-week low of $0.719.

Summary

Alaunos's preliminary proxy asks stockholders to approve converting Series B and Series C preferred into 381.4 million common shares, raising authorized stock to 400 million, a reverse split, a Cayman redomestication and new equity plans — the votes needed to complete the October Velaris merger.


Key Events · Corporate Governance and Compliance · TCRT

  • Preferred Conversion Vote

    Stockholders are asked to approve issuance of 381,403,000 common shares on conversion of 105,286 Series B and 276,117 Series C preferred shares, each converting at 1,000-for-1, under Nasdaq Rules 5635(a) and 5635(b).

  • Authorized Shares Raised to 400M

    The charter amendment lifts authorized common stock from 50,000,000 to 400,000,000; after conversion the company expects roughly 13,143,454 authorized shares to remain available, before any reverse split or new plan reserves.

  • Reverse Split and Cayman Move

    A reverse split of 1-for-2 up to 1-for-10 would be set by the Board with Lead Investor consent, and the company would redomicile from Delaware to the Cayman Islands, adopting a classified board and for-cause-only director removal by two-thirds special resolution.

  • Fairmount Takes Board Control

    On approval, directors Postma, Vieser and Jerman resign and three Lead Investor designees join Peter Harwin, giving Fairmount four of five seats; two Series B preferred directors each carry three votes, about 67% of a five-member board.


Analysis · TCRT · Life Sciences

This is the vote that makes the October 13 Velaris merger economically real. Holders are being asked to approve conversion of the Series B and Series C preferred into 381,403,000 common shares and to raise authorized common stock from 50,000,000 to 400,000,000. Without both, the preferred cannot convert, and the company has said holders could demand cash settlement at fair value. Legacy holders already own only about 1.0% of the combined company after the $350 million PIPE, so approval mainly ratifies a near-total change of control: Fairmount ends up with four of five board seats, two preferred directors carry three votes each, and the company plans to redomicile to the Cayman Islands with a classified board and for-cause-only director removal. The reverse split (1-for-2 to 1-for-10) is a separate Nasdaq price-support tool the Board can use even if the conversion fails. Failure to approve is the real risk here, not dilution that has already happened.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TCRT was trading at $1.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.7M. The 52-week trading range was $0.72 to $4.50. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TCRT - Latest Insights

TCRT
Nov 12, 2026, 7:49 PM EST
Filing Type: S-3
Importance Score:
7
Price at Filing: $1.60
Real-time Price: $1.56 info
Change: -$0.0399 (-2%) info
Market Cap: $6.729M info
TCRT
Oct 23, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.45
Real-time Price: $1.56 info
Change: -$0.890 (-36%) info
Market Cap: $6.729M info
TCRT
Oct 21, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.15
Real-time Price: $1.56 info
Change: -$1.59 (-50%) info
Market Cap: $6.729M info
TCRT
Oct 15, 2026, 7:55 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $2.88
Real-time Price: $1.56 info
Change: -$1.32 (-46%) info
Market Cap: $6.729M info
TCRT
Oct 15, 2026, 4:01 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $2.18
Real-time Price: $1.56 info
Change: -$0.620 (-28%) info
Market Cap: $6.729M info